RecruitingPhase 3NCT05890664

Colchicine After Electrocardioversion for Atrial Fibrillation

Colchicine After Electrocardioversion for Atrial Fibrillation - The COLECTRO-AF Trial

Sponsor

University Hospital, Basel, Switzerland

Enrollment

416 participants

Start Date

Apr 14, 2024

Study Type

INTERVENTIONAL

Conditions

Atrial Fibrillation Cardiac Arrhythmia

Summary

The purpose of this study is to investigate whether a 3 month treatment course of low-dose Colchicine decreases the recurrence of Atrial fibrillation (AF) after electrocardioversion (ECV) in patients with AF.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study tests whether taking colchicine (an anti-inflammatory drug) after a procedure to electrically restore normal heart rhythm (cardioversion) can reduce the chances of atrial fibrillation coming back. **You may be eligible if...** - You are over 18 - You had atrial fibrillation (irregular heartbeat) confirmed by an ECG - Your cardioversion was successful and your heart stayed in normal rhythm for at least 30 minutes afterward - You can give written consent **You may NOT be eligible if...** - Your heart did not return to normal rhythm after cardioversion, or it returned to irregular rhythm very quickly - You have conditions that make colchicine unsafe for you Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGColchicine

Colchicine 0.5 mg (oral) once daily for 90 days. The chemical name for colchicine is (S)-N-(5,6,7,9-tetrahydro-1,2,3,10-tetramethoxy-9 oxobenzol\[a\]heptalen-7-yl) acetamide. Colchicine consists of pale yellow scales or powder. It is soluble in water, freely soluble in alcohol, and slightly soluble in ether.

DRUGPlacebo

Matched placebo. Both the active drug and placebo will look similarly. The route and mode of administration is also similar to the active group.